Table 1.

TNBC cell lines and their most potent signaling protein kinase inhibitors in the Genomics of Drug Sensitivity in Cancer (GDSC1) database.

Cell Line	Most Potent PKI	Target	IC50 (nM)	Z-Score
BT-20	AKT inhibitor III	Akt	3505	−1
BT-549	GW441756	NTRK1	3036	−1.3
DU-4475	Dabrafenib	BRAF	6.3	−3.5
DU-4475	Trametinib	Mek	0.5	−2.1
HCC1143	Jak3_7406	Jak3	6312	−1.3
HCC1187	GW441756	NTRK1	89.7	−4.7
HCC1395	Panopanib	CSF1R, KIT, PDGFR	2432	−1.7
HCC1599	Jak1_3715	Jak 1	2185	−3.9
HCC1806	GSK1904529A	IGF1R, IR	3466	−1.4
HCC1937	WZ3105	Src, Rock2, NTRK2, FLT3	273	−0.8
HCC38	AKT inhibitor III	Akt 1, 2, 3	2085	−1.6
HCC70	AKT inhibitor III	Akt 1, 2, 3	775	−2.6
HCC70	MK-2206	Akt 1, 2	1245	−2.2
Hs-578-T	AT7868	Akt	1160	−2
MDA-MB-157	Motesanib	VEGFR, RET, KIT, PDGFR	6243	−0.8
MDA-MB-231	Alectinib	Alk	4639	−2
MDA-MB-436	GW441756	NTRK1	5057	−0.8
MDA-MB-453	FGFR_0939	FGFR4	643	−2.6
MDA-MB-468	Amuvatinib	Kit, PDGFRA, FLT3	1267	−2.2